NeuShen secures $80M to advance three clinical-stage brain therapies

NeuShen Therapeutics, a biotech with operations in Shanghai and Boston, has raised over $80 million in a Series B round. The company, led by an experienced drug developer with ties across the Pacific, will use the funds to push three brain-health candidates through clinical trials. The financing underscores continued investor interest in cross-border neuroscience ventures.

EXPANDED:

NeuShen Therapeutics maintains dual operational bases in Shanghai and Boston, positioning it within two major biotechnology hubs. The company's leadership includes a seasoned drug developer who maintains professional connections spanning the United States and China, bringing cross-cultural expertise to its research efforts.

The substantial Series B financing will be directed toward advancing three distinct brain-health treatment candidates that are already in clinical trials. This successful capital raise reflects a broader pattern of sustained investor confidence in neuroscience ventures operating across international borders, particularly those linking Asian and American